By Vivisum Partners, LLC Despite its strong efficacy, Remicade is facing increased competition from newer drugs and the prospect of pipeline drugs set to launch in the coming years.
|
By Vivisum Partners, LLC Among branded ulcerative colitis treatments, 84% of US gastroenterologists expect Zeposia to see an increase in prescription volume over the next 12 months, according to new research on the ulcerative colitis marketplace published by Vivisum Partners.
|
By Vivisum Partners, LLC New research into ulcerative colitis pipeline drugs found that US gastroenterologists who treat irritable bowel disease (IBD) have low awareness of some developing therapies.
|
By Vivisum Partners Newly published research found that several new ulcerative colitis drugs currently in development are providing excitement among gastroenterologists eager to add additional medicines to their current treatment options.
|